Oramed Pharmaceuticals Price to Free Cash Flow Ratio 2011-2024 | ORMP

Oramed Pharmaceuticals price to free cash flow ratio from 2011 to 2024. Price to free cash flow ratio can be defined as

Oramed Pharmaceuticals Price to Free Cash Flow Ratio 2011-2024 | ORMP

Oramed Pharmaceuticals price to free cash flow ratio from 2011 to 2024. Price to free cash flow ratio can be defined as
Related Stocks
Company NameMarket
Cap
Abbott Laboratories (ABT)$200B
Stryker (SYK)$141B
Boston Scientific (BSX)$128B
Medtronic (MDT)$113B
EssilorLuxottica (ESLOY)$112.7B
Lonza Group Ag (LZAGY)$45.3B
Haleon (HLN)$43.5B
GE HealthCare Technologies (GEHC)$40.4B
ResMed (RMD)$36.5B
Terumo (TRUMY)$30.3B
Koninklijke Philips (PHG)$25.9B
Zimmer Biomet Holdings (ZBH)$21.6B
Baxter (BAX)$18.4B
Insulet (PODD)$17.2B
Smith & Nephew SNATS (SNN)$10.8B
Bio-Rad Laboratories (BIO)$10.4B
BellRing Brands (BRBR)$8.9B
Demant (WILYY)$8.4B
Lantheus Holdings (LNTH)$6.1B
Haemonetics (HAE)$4.4B
ICU Medical (ICUI)$4.4B
TG Therapeutics (TGTX)$4.3B
Prestige Consumer Healthcare (PBH)$4B
Envista Holdings (NVST)$3.7B
Perrigo (PRGO)$3.7B
Neogen (NEOG)$3.4B
Agios Pharmaceuticals (AGIO)$3.1B
Shandong Weigao Medical Polymer (SHWGF)$3B
GN Store Nord (GNNDY)$2.9B
QuidelOrtho (QDEL)$2.6B